WO2006079923A3 - Form iv crystalline celecoxib - Google Patents

Form iv crystalline celecoxib Download PDF

Info

Publication number
WO2006079923A3
WO2006079923A3 PCT/IB2006/000190 IB2006000190W WO2006079923A3 WO 2006079923 A3 WO2006079923 A3 WO 2006079923A3 IB 2006000190 W IB2006000190 W IB 2006000190W WO 2006079923 A3 WO2006079923 A3 WO 2006079923A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline celecoxib
celecoxib
crystalline
benzenesulfonamide
pyrazol
Prior art date
Application number
PCT/IB2006/000190
Other languages
French (fr)
Other versions
WO2006079923A2 (en
Inventor
Michael Hawley
Guang Wei Lu
Brenda Mae Geiger
Mark Alan Smith
Ping Gao
Michael John Hageman
Gary Douglas Ewing
Original Assignee
Pharmacia & Upjohn Co Llc
Michael Hawley
Guang Wei Lu
Brenda Mae Geiger
Mark Alan Smith
Ping Gao
Michael John Hageman
Gary Douglas Ewing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Michael Hawley, Guang Wei Lu, Brenda Mae Geiger, Mark Alan Smith, Ping Gao, Michael John Hageman, Gary Douglas Ewing filed Critical Pharmacia & Upjohn Co Llc
Priority to JP2007552753A priority Critical patent/JP2008528568A/en
Priority to CA002595675A priority patent/CA2595675A1/en
Priority to EP06701524A priority patent/EP1846377A2/en
Publication of WO2006079923A2 publication Critical patent/WO2006079923A2/en
Publication of WO2006079923A3 publication Critical patent/WO2006079923A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel crystalline form of celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)­1H-pyrazol-1-yl] benzenesulfonamide), methods for its preparation, and pharmaceutical compositions comprising the same are described.
PCT/IB2006/000190 2005-01-31 2006-01-19 Form iv crystalline celecoxib WO2006079923A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007552753A JP2008528568A (en) 2005-01-31 2006-01-19 Celecoxib of type IV crystals
CA002595675A CA2595675A1 (en) 2005-01-31 2006-01-19 Form iv crystalline celecoxib
EP06701524A EP1846377A2 (en) 2005-01-31 2006-01-19 Form iv crystalline celecoxib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64850905P 2005-01-31 2005-01-31
US60/648,509 2005-01-31

Publications (2)

Publication Number Publication Date
WO2006079923A2 WO2006079923A2 (en) 2006-08-03
WO2006079923A3 true WO2006079923A3 (en) 2006-12-07

Family

ID=36607542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000190 WO2006079923A2 (en) 2005-01-31 2006-01-19 Form iv crystalline celecoxib

Country Status (4)

Country Link
EP (1) EP1846377A2 (en)
JP (1) JP2008528568A (en)
CA (1) CA2595675A1 (en)
WO (1) WO2006079923A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150144A2 (en) * 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
CN103524416B (en) * 2013-10-29 2016-08-17 湖北华世通生物医药科技有限公司 A kind of Novel celecoxib crystal form A and preparation method thereof
CN103539739B (en) * 2013-10-30 2016-02-10 中美华世通生物医药科技（武汉）有限公司 A kind of Novel celecoxib crystal form B and preparation method thereof
AR126414A1 (en) * 2021-07-09 2023-10-11 US Nano Food & Drug INC PRODUCTION METHOD OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167355A1 (en) * 2000-06-26 2002-01-02 Fako Ilaclari A.S. A crystalline form of celecoxib
US20040087640A1 (en) * 1999-12-08 2004-05-06 Ferro Leonard J. Polymorphic crystalline forms of celecoxib
WO2005014546A1 (en) * 2003-08-08 2005-02-17 Hetero Drugs Limited Novel crystalline forms of celecoxib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087640A1 (en) * 1999-12-08 2004-05-06 Ferro Leonard J. Polymorphic crystalline forms of celecoxib
EP1167355A1 (en) * 2000-06-26 2002-01-02 Fako Ilaclari A.S. A crystalline form of celecoxib
WO2005014546A1 (en) * 2003-08-08 2005-02-17 Hetero Drugs Limited Novel crystalline forms of celecoxib

Also Published As

Publication number Publication date
WO2006079923A2 (en) 2006-08-03
JP2008528568A (en) 2008-07-31
CA2595675A1 (en) 2006-08-03
EP1846377A2 (en) 2007-10-24

Similar Documents

Publication Publication Date Title
WO2007076260A3 (en) Farnesoid x receptor agonists
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
MX2007014892A (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl) phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin -2-ylamino]propionate.
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2011053938A8 (en) Methods and compositions for treating cancer
WO2005087700A3 (en) Bisphenyl compounds useful as vitamin d3 receptor agonists
WO2007003961A3 (en) Gpcr agonists
IL192298A (en) Heterocyclic compounds, pharmaceutical acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2008060476A3 (en) Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2009001060A3 (en) Use of compounds for preparing anti-tuberculosis agents
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2007149730A3 (en) Inhibitors of akt (protein kinase b)
WO2007006533A3 (en) Indolylmaleimide derivatives
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2009047565A3 (en) Zibotentan composition containing mannitol and/or microcrystalline cellulose
WO2007106022A3 (en) A new crystalline form g of (5s) -5- [4- (5-chloro-pyridin-2- yloxy) -piperidine-1-sulfonylmethyl] - 5 -methyl -imidazolidine - 2,4-dione (i) and intermediates thereof.
WO2006130080A3 (en) Quinoline derivatives as nk3 anatgonists
WO2007064719A3 (en) Formulations of quinolinones
WO2006079923A3 (en) Form iv crystalline celecoxib
WO2005097787A3 (en) Novel benzothiazoles and the use thereof as medicaments
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006036932A3 (en) Sulfonamides and uses thereof
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006701524

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2595675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007552753

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2006701524

Country of ref document: EP